Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of allogeneic unmodified Gamma Delta (γδ) T cells (CTM-GDT) for no-option cancer patients in Malaysia

Next Previous
Trial Profile

A multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of allogeneic unmodified Gamma Delta (γδ) T cells (CTM-GDT) for no-option cancer patients in Malaysia

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gamma-delta-T-cell-therapy-Cytomed-Therapeutics (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man

Most Recent Events

  • 22 Dec 2025 New trial record
  • 08 Dec 2025 According to CytoMed Therapeutics media release, company announced that it has entered into a Memorandum of Understanding with Universiti Malaya Medical Centre (UMMC) to establish a multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of CytoMeds patented allogeneic unmodified Gamma Delta T cells (CTM-GDT) for no-option cancer patients in Malaysia.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top